Page 77 - Read Online
P. 77
Klugmann et al. Rare Dis Orphan Drugs J 2023;2:8 https://dx.doi.org/10.20517/rdodj.2023.05 Page 9 of 9
Conflicts of interest
Klugmann M was employed by the company Boehringer Ingelheim Pharma GmbH & Co. KG. All authors
declared that there is no conflict of interest.
Ethical approval and consent to participate
This study was approved by the UNSW Sydney Human Research Ethics Advisory Panel D.
Consent for publication
Not applicable.
Copyright
© The Author(s) 2023.
REFERENCES
1. Abbott JA, Francklyn CS, Robey-Bond SM. Transfer RNA and human disease. Front Genet 2014;5:158. DOI PubMed PMC
2. Ognjenović J, Simonović M. Human aminoacyl-tRNA synthetases in diseases of the nervous system. RNA Biol 2018;15:623-34. DOI
PubMed PMC
3. Antonellis A, Green ED. The role of aminoacyl-tRNA synthetases in genetic diseases. Annu Rev Genomics Hum Genet 2008;9:87-107.
DOI PubMed
4. Taft RJ, Vanderver A, Leventer RJ, et al. Mutations in DARS cause hypomyelination with brain stem and spinal cord involvement and
leg spasticity. Am J Hum Genet 2013;92:774-80. DOI PubMed PMC
5. Wolf NI, Toro C, Kister I, et al. DARS-associated leukoencephalopathy can mimic a steroid-responsive neuroinflammatory disorder.
Neurology 2015;84:226-30. DOI PubMed PMC
6. Muthiah A, Housley GD, Klugmann M, Fröhlich D. The leukodystrophies HBSL and LBSL-correlates and distinctions. Front Cell
Neurosci 2020;14:626610. DOI PubMed PMC
7. Scheper GC, van der Klok T, van Andel RJ, et al. Mitochondrial aspartyl-tRNA synthetase deficiency causes leukoencephalopathy
with brain stem and spinal cord involvement and lactate elevation. Nat Genet 2007;39:534-9. DOI PubMed
8. Dogan SA, Pujol C, Maiti P, et al. Tissue-specific loss of DARS2 activates stress responses independently of respiratory chain
deficiency in the heart. Cell Metab 2014;19:458-69. DOI PubMed
9. Fröhlich D, Suchowerska AK, Spencer ZH, et al. In vivo characterization of the aspartyl-tRNA synthetase DARS: homing in on the
leukodystrophy HBSL. Neurobiol Dis 2017;97:24-35. DOI PubMed
10. Fröhlich D, Mendes MI, Kueh AJ, et al. A hypomorphic Dars1D367Y model recapitulates key aspects of the leukodystrophy HBSL.
Front Cell Neurosci 2020;14:625879. DOI PubMed PMC
11. Klugmann M, Kalotay E, Delerue F, et al. Developmental delay and late onset HBSL pathology in hypomorphic Dars1M256L mice.
Neurochem Res 2022;47:1972-84. DOI PubMed PMC
12. Fröhlich D, Suchowerska AK, Voss C, et al. Expression pattern of the aspartyl-tRNA synthetase DARS in the human brain. Front Mol
Neurosci 2018;11:81. DOI PubMed PMC
13. Lipman NS, Jackson LR, Trudel LJ, Weis-Garcia F. Monoclonal versus polyclonal antibodies: distinguishing characteristics,
applications, and information resources. ILAR J 2005;46:258-68. DOI PubMed
14. Howat WJ, Lewis A, Jones P, et al. Antibody validation of immunohistochemistry for biomarker discovery: recommendations of a
consortium of academic and pharmaceutical based histopathology researchers. Methods 2014;70:34-8. DOI PubMed PMC